Home›Stocks›QNRX

QNRX — structural market context

Quoin Pharmaceuticals, Ltd. Am

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 21. Each line shows the earlier value, the later value and their dates.

Price

Close $3.99 (Oct 21) vs $4.04 (Oct 20): −1.24%.

Volume

0.16× its 20-session average (48K) on Oct 21.

Includes pre- and post-market trading.

Short interest

Short interest 65K shares (settlement Sep 30) vs 126K (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 9 days with fails, largest 19K shares on Sep 29.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 7 days with fails, largest 71K shares on Sep 1.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

QNRX events and their magnitude

Latest SEC filing in the event study

8-K 7.01 · Regulation FD disclosure · filed 2026-10-20 · View on sec.gov ↗

…

Open the Event Study →

QNRX short interest & days to cover

SHARES SHORT
65K
% OF FLOAT
4.5%
DAYS TO COVER
1.4
CHANGE VS PRIOR
-48.2%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (22d ago)

QNRX fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 22d4K$4.88
2026-09-29 · 23d19K$5.37
2026-09-28 · 24d278$6.43

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

QNRX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 4 purchases · 0 sales · 3 filings not counted

InsiderTypeSharesValueFiled
Carter Denise P. · director, officer: Chief Operating OfficerPurchase (P)20K$100K2026-09-01
Carter Denise P. · director, officer: Chief Operating OfficerPurchase (P)10K—*2026-09-01
Myers Michael · director, officer: Chief Executive OfficerPurchase (P)20K$100K2026-09-01
Myers Michael · director, officer: Chief Executive OfficerPurchase (P)10K—*2026-09-01
Lawlor Sally Bridget · officer: Chief Financial OfficerPurchase (P)10K$50K2026-09-01

*Value not shown: the filed price could not be checked against the U.S. listing.

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

QNRX offering filings (SEC)

1 SEC filing in the last 90 days, by filing date.

FiledFormDocument
2026-09-18Registration statement (Form S-3) S-3View on sec.gov ↗

See all filings on SEC EDGAR ↗

SEC filings listed by filing date. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price. Some of these filings cover debt securities or resales by existing holders. A filing is made by the issuer and appears under each of its tickers. Source: SEC EDGAR daily index; each filing links to its page on sec.gov.

Source: SEC EDGAR daily index, read once a day after the SEC publishes it (around 10:30 pm ET). Forms covered: S-1, S-3, F-1 and F-3 with their amendments, S-3ASR, F-3ASR, 424B4 and 424B5. · as of 2026-10-21

QNRX analyst ratings

FirmActionRatingPublished
BTIGinitialiseBuy2026-10-12
Lake StreetinitialiseBuy2026-09-23
Lake Streetprice_target—2026-09-23

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is QNRX's short interest?
As of the FINRA settlement date 2026-09-30, QNRX had 65K shares sold short — 4.5% of its float, with 1.4 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying QNRX?
In the last 12 months of SEC Form 4 filings, QNRX recorded 4 insider purchases and 0 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). 3 filings not counted: the filed price could not be checked against the U.S. listing. These are attributed public records — information, not instruction.
What are the SEC offering filings listed for QNRX?
They are registration statements (Forms S-1, S-3, F-1 and F-3, with their amendments and the S-3ASR and F-3ASR automatic shelf forms) and prospectuses filed under Rule 424(b)(4) or 424(b)(5). In the last 90 days the issuer of QNRX filed 1; the most recent was a registration statement (Form S-3) on 2026-09-18. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price, and some of these filings cover debt securities or resales by existing holders.
What do analysts say about QNRX?
The most recent action: BTIG initialise to Buy on 2026-10-12. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell QNRX?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with Q

QCOM · QUALCOMM IncorporatedQMLS · QumulusAI, Inc.QQQ · Invesco QQQ Trust, Series 1QXO · QXO, Inc.Q · Qnity Electronics, Inc.QLYS · Qualys, Inc.All Q →

QNRX: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.